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Abstract
Background: There is conclusive evidence from observational data and three randomized controlled trials that circumcised
men have a significantly lower risk of becoming infected with the human immunodeficiency virus (HIV). The aim of this
study was to systematically review economic evaluations on adult male circumcision (AMC) for prevention of heterosexual
acquisition of HIV in men.
Methods and Findings: Studies were identified from the following bibliographic databases: MEDLINE (Ovid), EMBASE
(Ovid), Cochrane Library (Wiley’s internet version), NHS EED and DARE Office of Health Economics HEED. The searches were
conducted in November 2009. The Drummond 10-point checklist was used for methodological critique of the economic
evaluations. Cost data were inflated and converted to 2008 US dollars (US$). Of 264 identified papers, only five met the
inclusion criteria and were included in the review. The studies were published between 2006 and 2009. Most of the studies
were carried out from the perspective of government healthcare payer. The time horizon ranged from 10 to 20 years. All
studies reported that AMC is cost-effective. The reported cost per HIV infection averted ranged from US$174 to US$2808.
The key driver of the cost-effectiveness models was circumcision efficacy.
Conclusions: All published economic evaluations offered the same conclusion that AMC is cost-effective and potentially
cost-saving for prevention of heterosexual acquisition of HIV in men. On these grounds, AMC may be seen as a promising
new form of strategy for prevention of HIV and should be implemented in conjunction with other evidence-based
prevention methods.
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Introduction
Male circumcision is one of the oldest and most common surgical
procedures worldwide. It may be undertaken for religious, cultural,
social and medical reasons. There is conclusive evidence from
observational data [1,2,3,4,5,6] and three randomized controlled
trials [7,8,9] that circumcised men have a significantly lower risk of
becoming infected with the human immunodeficiency virus (HIV).
Several reviews have been reported on the effectiveness of adult
male circumcision (AMC) for prevention of heterosexual acquisi
tion of HIV in men [10,11,12,13,14,15,16,17,18,19,20]. While the
literature has focused on the effectiveness alone, we argue that there
has not been commensurate interest in economic evaluations.
Economic evaluation provides a useful framework to assist policy
makers in allocating resources across competing needs. HIV/AIDS
is a considerable burden on society resources, and prevention
provides a cost-beneficial solution to address these consequences
[21]. Sub-Saharan Africa is more heavily affected by Human
immunodeficiency virus (HIV) and acquired immunodeficiency
syndrome (AIDS) than any other region of the world [22].
Estimated 22.5 million people were living with HIV at the end of
2007 and approximately 1.7 million additional people were infected
with HIV during that year [22]. In just the past year, the AIDS
epidemic in Africa had claimed the lives of estimated 1.6 million
people in this region. More than 11 million children have been
orphaned by AIDS [22].
To our knowledge, no systematic review of the peer-reviewed
economic evaluations literature on AMC for prevention of
heterosexual acquisition of HIV in men has been published to
date. A goal of systematic review is to provide the clinician,
researcher or policy makers with a balanced appraisal of the
totality of the evidence in an area by reading one review, contrary
to a multitude of individual studies. This allows for a more
objective appraisal of the evidence, which may lead to resolution of
uncertainty and disagreement. Therefore, the objectives of this
systematic review were to identify published economic evaluations
on AMC for prevention of heterosexual acquisition of HIV in men
and to identify areas that merit further study.
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Methods
Eligibility Criteria
Inclusion and exclusion criteria applied for economic searches
are summarised below:
N Study design: cost-effectiveness analysis, cost-utility analysis,
or cost-benefit analysis
N Population: adult male in sub-Saharan Africa
N Intervention: adult male circumcision (AMC)
N Comparator: no AMC
Information Sources and Search strategy
A comprehensive search for literature on the cost-effectiveness
of AMC versus no AMC for prevention of heterosexual acquisition
of HIV in men was conducted. Studies were identified from the
following bibliographic databases: MEDLINE (Ovid), EMBASE
(Ovid), Cochrane Library (Wiley’s internet version), NHS EED
and DARE Office of Health Economics HEED. The searches
were conducted in November 2009. Searches were not limited by
date and there were no language restrictions. Search keywords
included male circumcision, circumcision, and adult male
circumcision. These keywords were combined with an economic
study filter based on the Centre for Review Disseminations model
[23,24]. We also checked the reference lists of all studies identified
by the above methods.
Study Selection
One reviewer applied the inclusion and exclusion criteria. These
were checked by a second reviewer. Disagreements were resolved
by discussion.
Data Collection Process and Data Items
For each identified study that met the selection criteria, the
following data were extracted country, study design, population,
intervention, comparator, perspective, model type, primary
outcome, discount rate, time horizon, and price year on to an
Excel spreadsheet. The main characteristics, quality assessment
(see below) and results of included economic evaluations were
tabulated. One review author extracted data and the second
author checked the extracted data.
Quality Assessment
Identified economic evaluations were also assessed against the
Drummond 10-point checklist [25]. The checklist was developed
to assess/critique the quality of an economic evaluation.
Drummond checklists consider the following: description of
interventions; study design; identification, measurement and
valuation of costs and consequences; discounting; a clear results
with sensitivity and uncertainty analysis; and discussion of results
in the context of policy relevance and existing literature.
Summary Measures
For the primary outcome, the preferred measures were cost per
HIV infection averted (HIA), and incremental cost-effectiveness
ratio (cost per quality adjusted life years (QALY) gained and cost
per disability adjusted life years (DALY) averted). Net cost saving
was also considered.
In order to make different cost data comparable, the cost data
were inflated to 2008 prices using the prices inflation index [26].
For those studies that did not report price year, the year the study
was published was used for inflation of cost data. This review was
performed according to the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) [27,28].
Results
Study Selection
The search of electronic databases produced a total of 264
citations (Figure 1). After adjusting for duplicates 205 remained.
Of these, 190 studies were discarded because after reviewing the
abstracts it appeared that these papers clearly did not meet the
inclusion criteria. The full text of the remaining 15 citations was
examined in more detail. Ten studies were discarded for the
following reasons: cost-analysis (n = 3) [29,30,31], neonatal
circumcision (n = 3) [32,33,34], correspondence (n = 2) [35,36],
and population based on high-income country (n = 2) [37,38]. Five
studies [39,40,41,42,43] met the inclusion criteria and were
included in the systematic review.
Study Characteristics
Table 1 shows the characteristics of the included studies. The
studies were published between 2006 and 2009. Studies popula-
tion was from Uganda [40], South Africa [39], Mozambique [42],
and Botswana [43]. Auvert et al 2008 [41] included data from the
following 16 countries in sub-Saharan Africa: Botswana, Burundi,
Central African Republic, Kenya’s Nyanza province, Lesotho,
Liberia, Malawi, Mozambique, Namibia, Rwanda, South Africa,
Swaziland, Tanzania, Uganda, Zambia and Zimbabwe. All studies
[39,40,41,42,43] were cost-effectiveness analyses and primary
outcome was cost per HIV infection averted (HIA). Most studies
were carried out from the perspective of government healthcare
payer. All studies [39,40,41,42,43] compared cost-effectiveness of
adult male circumcision (AMC) versus no AMC. The model types
included epidemiologic [39,41,43], stochastic [40], and costing
model [42]. Four studies used 3% discount rate [39,41,42,43].
One study did not report discount rate [40]. The time horizon
ranged from 10 to 20 years.
Validity Assessment
Details of the quality of assessments can be found in Table 2.
1. Was a well-defined question posed in answerable
form? Three studies [39,40,41] had clearly defined questions,
i.e., to assess the cost-effectiveness of AMC in prevention of HIV.
Two studies did not state their research question clearly [42][43].
2. Was a comprehensive description of the competing
alternatives given? All studies [39,40,41,42,43] described
competing alternatives, AMC versus no AMC.
3. Was the effectiveness of the programmes or services
established? Evidence of effectiveness came from the
observational studies or from the trial results [7,8,9]. Kahn et al
2006 [39] defined effectiveness as the number of HIA, which was
estimated by dynamically projecting over 20 years the reduction in
HIV incidence observed in the Orange Farm [7](OF, Gauteng
Province, South Africa). Auvert et al 2008 [41] and Fieno et al
2008 [42] also used evidence of effectiveness from OF trial [7].
Bollinger et al 2009 [43] used evidence from three trials [7,8,9].
Gray et al 2007 [40] effectiveness parameters were based on an
observational study in a rural population of Rakai District, south-
western Uganda. Gray et al 2007 [40] assumed that circumcision
might reduce the incidence of HIV incidence rate ratios (IRR)
varying from 0.3 to 0.6. Efficacy, the reduced incidence of HIV
afforded by circumcision, was estimated from 1-IRR.
4. Were all the important and relevant costs and
consequences for each alternative identified? All studies
[39,40,41,42,43] considered cost of AMC. Except for Gray et al
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Figure 1. Flowchart for study selection.
doi:10.1371/journal.pone.0009628.g001
Table 1. General characteristics of included studies.
Study ID
Characteristics Gray 2007 [40] Kahn 2006 [39] Auvert 2008 [41] Fieno 2008 [42] Bollinger 2009 [43]
Country Uganda South Africa SSA Mozambique Botswana
Study design CEA CEA CEA CEA CEA
Intervention AMC AMC AMC AMC AMC
Comparator No AMC No AMC No AMC No AMC No AMC
Perspective Not reported government
healthcare payer
government
healthcare payer
government
healthcare payer
government
healthcare payer
Model Stochastic simulation Epidemiologic model Epidemiologic model Costing model Epidemiologic model
Primary outcome Cost per HIA Cost per HIA Cost per HIA Cost per HIA Cost per HIA
Discount rate (%) NR 3 3 3
Time horizon (years) 10 20 10–20 20 17
Results
Cost per HIA(US$)* 2808 193 174 390 642
HIA: HIV infection averted; CEA: Cost-effectiveness Analysis; AMC: Adult male circumcision; SSA: sub-Saharan Africa.
*Value in 2008 US dollars.
doi:10.1371/journal.pone.0009628.t001
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2007 [40], studies [39,41,42,43] considered lifetime medical cost
of treating HIV. Only one study included complications associated
with AMC in the cost-effectiveness model [39].
5. Were costs and consequences measured accurately in
appropriate physical units? Most studies estimated cost of
AMC and lifetime medical treatment of HIV from published
studies. Number of HIV infections averted was the primary
outcome in all studies. Fieno et al 2008 [42] also valued outcome
in DALYs averted. Most studies extrapolated the number of HIV
infection averted beyond the trials period.
6. Were costs and consequences valued credibly? Kahn et
al. 2006 [39] cost of performing an AMC was based on the
estimate from the OF RCT [7]. Kahn et al. 2006 [39] assumed
zero additional training and physical infrastructure development
costs in connection with high levels of circumcision coverage. The
cost per AMC was varied by 650% to reflect these potential
efficiencies or inefficiencies of scale-up. The cost of adverse events
was included and standardized for 1,000 individuals. The lifetime
cost of HIV treatment was based on Cleary et al. [44] data from
pilot clinics (in South Africa) for a prospective disease state model.
Cleary and colleagues [44] estimated a lifetime discounted cost of
US$11,948 with antiretroviral therapy (ART) and US$3,793
without ART. However, Kahn et al. 2006 [39] used US$8,000 as
the base case value, implying 50% access to ongoing ART, and
explored a wide range from US $4,000 to US$12,000.
Gray et al 2007 [40] used the estimated cost per surgery in the
Rakai trial [45] (US$69) to estimate the cost per HIA over a period
of 10 years. Auvert et al 2008 [41] explored a public cost scenario
assuming the use of government health infrastructures only and a
private cost scenario assuming reliance on private health care
providers only. Program costs were composed of initial and annual
costs. In the public cost scenario, initial costs were per
circumcision facility (for medical equipment and certification)
and for training circumcisers. Annual costs included the oversight
and promotion of AMC, the salaries of full-time circumcisers,
surgical staff and counsellors, the direct non-salary cost of each
AMC (i.e., surgical supplies), facility overhead (i.e., operating costs)
and program overhead. In the private cost scenario, all facility-
level costs were included in the price per AMC paid to providers.
No initial costs were included because these providers were
already equipped to perform AMC. The price of each AMC
covered salaries of circumcisers, other health staff, counselling,
surgical supplies, follow-up, treatment of adverse events and
operating costs. In addition to direct provider payments, Auvert et
al 2008 [41] also assumed annual program overhead costs of 10%
to cover the public promotion of AMC. In order to estimate costs
and savings from HIV treatment, Auvert et al 2008 [41] assumed
that 30% of HIV-infected individuals eligible for antiretroviral
treatment were receiving it. The averted cost of medical treatment
for HIV over time was a function of the number of HIV infections
averted each year and the rate of disease progression, combined
with associated medical costs.
Fieno et al 2008 [41] reported detail breakdown of AMC
costing model estimates under different scenarios. The costing
model was broken down into seven cost inputs: personnel (salaries
and training), surgical equipment and supplies, bandages and
cleaning supplies, monitoring and evaluation (M & E), adminis-
tration, rural coverage, and adverse events due to the surgery.
Fieno et al 2008 [41] assumed the value of medical care per HIV
infection was to be the cost of two years of anti-retroviral therapy
(ART) (US$500) in Mozambique or US$1000. Bollinger et al 2009
[43] used unit cost of an uncomplicated AMC of US$48 in the
public sector as provided by Botswana national strategy. In
addition, Bollinger et al 2009 [43] also developed three other unit
costs: (1) a neonatal circumcision unit cost of US$38 (assumed to
be 20% lower than the adult cost, due to lower complication rates
and lower costs for commodities), (2) private provider unit costs for
both adult and neonatal circumcisions of US$60 and US$48
(assumed to be 5% higher than the relevant public sector costs).,
and (3) user fees of US$1 for public sector and US$25 for private
providers were assumed.
Kahn et al. 2006 [39] defined effectiveness as the number of
HIV infections prevented per 1,000 newly circumcised men over a
specified number of years. The effectiveness was calculated as the
Table 2. Quality of included studies.
Study ID
Criteria Gray 2007 [40] Kahn 2006 [39] Auvert 2008 [41] Fieno 2008 [42] Bollinger 2009 [43]
1) Well defined question stated? yes Yes Yes Partially Partially
2) Description of alternative given? Yes Yes Yes Yes Yes
3) Evidence of effectiveness
established?
Cannot tell Yes Yes Yes Yes
4) Relevant costs and outcomes
identified?
Partially Partially Partially Partially Partially
5a) Costs measured accurately? No Yes Yes Yes Yes
5b) Outcomes measured accurately? Yes Yes Yes Yes Yes
6a) Costs valued credibly? Yes Yes Yes Yes Yes
6b) Outcomes valued credibly? Yes Yes Yes Yes Yes
7a) Costs discounted? No Yes Yes no Yes
7b) Outcomes discounted? No Yes Cannot tell no No
8) Incremental analysis performed Yes Yes Yes Yes Yes
9) Sensitivity analysis performed Yes Yes Yes No Yes
10) Results presented clearly and
discussed?
Yes Yes Yes yes Yes
doi:10.1371/journal.pone.0009628.t002
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product of the number of HIV susceptible, the HIV incidence
rate, the protective effect of AMC (adjusted for risk compensation),
the projection period (in years), and an epidemic multiplier. Kahn
et al. 2006 [39] estimated net DALYs by subtracting the increase
in DALYs due to adverse events from the reduction in DALYs due
to HIA. The reduction in DALYs from HIV was calculated by
multiplying HIA by previously reported discounted DALY
changes with ART (ten DALYs) and without (21 DALYs),
assuming 50% on ART. Gray et al 2007 [40] calculated the
number of HIV infections potentially averted by each surgery
from the total number of incident cases expected in the population
in the absence of a circumcision program minus the number of
incident cases estimated with varying circumcision efficacies.
Auvert et al 2008 [41] estimated effects of AMC on HIV as a
function of time and parameters were based on published studies.
Fieno et al 2008 [41] assumed the number of DALYs per HIV/
AIDS mortality to be 15.5 years. The benefits of AMC were
estimated from the Kahn et al. 2006 [39] cost-effectiveness model.
Bollinger et al 2009 [43] calculated number of AMC that are
required in order to avert one HIV infection by dividing the
increase in the number of AMC performed by the number of HIA
over the relevant time period.
7. Were costs and consequences adjusted for differential
timing? Most studies [39,41,42,43] discounted cost accrued
beyond 1 year. Kahn et al 2006 [39] was the only study that
reported that future benefit was discounted.
8. Was an incremental analysis of costs and consequences
of alternatives performed? All studies [39,40,41,42,43]
calculated program cost per HIA. Fieno et al 2008 [42] also
calculated the cost of one DALY saved from HIV infection
averted.
9. Was allowance made for uncertainty in the estimates of
costs and consequences? Except for Fieno et al 2008 [42],
studies reported at least one form of sensitivity analyses. Gray et al
2007 [40] explored the effect of variation program coverage and
circumcision efficacy on the cost per HIA. Kahn et al 2006 [39]
conducted sensitivity analyses to examine the effects of all input
uncertainty and program coverage using one-way, three-way and
multivariate (using Monte Carlo simulations) sensitivity analyses.
Auvert et al 2008 [41] explored a public cost scenario assuming
the use of government health infrastructures only and a private
cost scenario assuming reliance on the private health care
providers only. In addition, Auvert et al 2008 [41] also
considered the effect of different time horizon and program
coverage on cost per HIA. Bollinger et al 2009 [43] examined the
effects in variation in program effectiveness, discount rate, and
lifetime cost of ART on the cost per HIA.
10. Did the presentation and discussion of study results
include all issues of concern to users? Most of the studies
discussed issue of availability, affordability, and sustainability of
their findings.
Outcome Measures
Table 1 also shows the estimated cost per HIA from the five
studies. Gray et al 2007 [40] reported that the cost per HIA over
10 years could range from US$2808 with 60% circumcision
efficacy, to US$4173 with 40% circumcision efficacy. Kahn et al.
2006 [39] estimated the cost per HIA over 20 years at US$193.
Kahn et al. 2006 [39] also reported that the cost-effectiveness
model was sensitive to the cost of AMC, cost of averted HIV
treatment, the protective effect of AMC, and HIV prevalence.
With an HIV prevalence of 8.4%, the cost of per HIA increased
nearly 3-fold to US$588. Cost-effectiveness improves by less than
US10$ when AMC intervention coverage is 50% of full coverage.
Auvert et al 2008 [41] found that the estimated costs per HIA over
10 and 20 years were US$351 (US$271 to US$473) and US$174
(US$138 to US$232) respectively. Fieno et al 2008 [41] estimated
the cost per HIA over 20 years at US$390. Bollinger et al 2009
[43] estimated the cost per HIA with 60% circumcision efficacy at
US$642. However, the cost-effectiveness model was sensitive to
AMC effectiveness. At 75% and 30% circumcision efficacy, the
costs per HIA were US$508 and US$1313 respectively.
The reported cost savings varied across the studies. Kahn et al.
2006 [39] found that after adjustment for averted lifetime HIV
medical costs, the net saving was US$2573 per AMC. Auvert et al
2008 [41] found that the estimated net savings over 20 years were
US$2.4 billion (95% percentile interval 1.5 to 3.5). Fieno et al
2008 [41] reported that the saving from the AMC in terms of
medical costs alone would accrue over 20 years to US$234.0
million. Bollinger et al 2009 [43] estimated net savings over 17
years with 60% circumcision efficacy at US$10,616. Only study
reported cost per DALYs averted [41]. Fieno et al 2008 [41]
reported that cost was US$7.8 per DALY.
Discussion
Main Findings
This systematic review of economic evaluations of adult male
circumcision (AMC) for prevention of heterosexual acquisition of
HIV in men provides compelling evidence that AMC is within the
range of what is generally regarded as cost-effective, even cost-
saving, intervention. The reported cost per HIA ranged from
US$174 in Auvert et al 2008 [41] to as much as US$2808 in Gray
et al 2007 [40]. The key driver of cost-effectiveness models was
circumcision efficacy. Except for Gray et al 2007 [40], studies used
evidence of effectiveness from OF trial [7]. Thus, possible
explanation for the high cost per HIA reported by Gray et al
2007 [40] in comparison to other studies could be due to the fact
that the model effectiveness data was based on observational study.
However, these findings are comparable with other prevention
and treatment strategies in developing countries in terms of
economic criteria. Recent reviews of HIV prevention cost-
effectiveness suggest a range of $10 to more than $10,000 per
HIA [46,47,48]. Commercial sex worker interventions and mass-
media campaign cost just over US$50 per HIA. Second-
generation female condom cost US$985 per HIA. Blood safety
measures cost US$41–246 per HIA. Diagnosis and treatment of
sexually transmitted infections cost US$250 per HIA. Voluntary
testing and counselling cost S$264–367 per HIA; and intervention
for reducing mother-to-child transmission cost US$84–714 per
HIA.
Study Strengths and Limitations
The strengths of this study are that, to our knowledge, it
provides the most comprehensive review to date of economic
evaluations of male circumcision for prevention of heterosexual
acquisition of HIV in men in sub-Saharan; and it is the first review
in this area to critique the quality of modelling approaches used in
the economic evaluations. The search process was elaborate and to
our knowledge no other studies were available for review. In
addition, we used a standard checklist to appraise the quality of
economic evaluations. The reporting of this review conforms to
PRISMA guideline [27,28].
There are number of limitations associated with these studies.
Most of these studies did not considered complications associated
with AMC in their cost-effectiveness models. It has been reported
that high complication rates challenge the implementation of male
circumcision for HIV prevention in Africa [49]. Another
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important limitation of these studies, except for Kahn et al 2006
[39], most of the authors did not considered multivariate
sensitivity analysis. The uncertainty in the evidence base needs
to be reflected in the model. To simultaneously assess the
implications of uncertainty in all elements of evidence, probabi-
listic analysis should be used to establish the decision uncertainty
associated with each public health intervention being compared
[50,51]. This informs decision-makers about the probability of
each strategy being the most cost-effective conditional on the value
that the decision maker places on a unit of health gain. Such
methods can also be used to provide an opportunity to apply value
of information (VOI) methods to inform priority setting in
research [52,53,54]. Generalizability of the findings is also an
important limitation. Most of the studies were based on OF trial
[7]. The OF trial [7] was conducted in a single country and used
prevailing or local prices to calculate costs. Economic evaluation
carried out alongside a randomised controlled trial may differ
significantly from usual practice or care [55]. We recommend that
future economic evaluations address these limitations and be
guided in part by the checklists available for assessing economic
evaluations. Economic evaluation provides a useful framework to
assist policy makers in allocating resources across competing
needs. HIV/AIDS is a considerable burden on society resources,
and prevention provides a cost-beneficial solution to address these
consequences. To better inform the decision-making process,
researchers must continue to produce high-quality, methodolog-
ical, comparable and scientifically credible economic evaluations.
All published economic evaluations offered the same conclusion
that AMC is cost-effective and potentially cost-saving for
prevention of heterosexual acquisition of HIV in men. On these
grounds, AMC may be seen as a promising new form of strategy
for prevention of HIV. However, we believed like others that
AMC should never replace other known methods of HIV
prevention. AMC should be considered as part of a comprehensive
HIV prevention package, such as, promoting delay in the onset of
sexual relations, abstinence from penetrative sex and reduction in
the number of sexual partners; providing and promoting the
correct and consistent use of male and female condoms; providing
HIV testing and counselling services; and providing services for
the treatment of sexual transmitted infections.
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